Microinjection

Global Rat Model Market to Reach $2.41 Billion by 2030 with a CAGR of 7.06%: Key Insights and Growth Factors Unveiled

Retrieved on: 
Tuesday, October 31, 2023
Rat, Gene editing, Human, Incidence, Molecular biology, Therapy, Vaccine, Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase, Toxicology, CRISPR, Prevalence, Embryonic stem cell, Human Genome Project, Phenotype, Research, Application, Microinjection, Growth, Disease, COVID-19, Breeding, Outcrossing, Envigo, USD, ZFN, GEM, Agriculture, Medical device

The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.

Key Points: 
  • The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.
  • Genetically modified organisms are extensively used in research for identifying potential therapeutic targets and further validation of the same.
  • The extensive healthcare-based research has driven the market for understanding diseases and genetic illnesses of humans.
  • Increased spending on research and growing number of clinical trials are the key factors contributing to the market growth.

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Retrieved on: 
Thursday, June 1, 2023
AMD, Pharming, Eye, Clinical trial, TKI, CLS, Microinjection, Axitinib, Visual acuity, Disease, Pharmaceutical industry

ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment has opened in ODYSSEY, its Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoroidal delivery in neovascular age-related macular degeneration (wet AMD).

Key Points: 
  • ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment has opened in ODYSSEY, its Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoroidal delivery in neovascular age-related macular degeneration (wet AMD).
  • “With the ODYSSEY clinical trial now open for enrollment, we are excited to continue exploring the potential of CLS-AX to provide an effective and less burdensome treatment option in the multi-billion-dollar wet AMD market,” said George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer.
  • We believe that the number of participants, duration, and outcome measures of the study will provide the necessary clinical data to design a CLS-AX Phase 3 program.
  • We are targeting a total of 30 U.S. based clinical trial sites for ODYSSEY and expect to report topline data from the trial in the third quarter of next year,” concluded Dr. Lasezkay.

Global Skin Boosters Market Report 2023: Sector is Expected to Reach $2.1 Billion by 2030 at a CAGR of 9.6% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 17, 2023
Cosmetics, Retail, Mineral, BBC, COVID-19, Elastin, Skin, Epidermis, Woman, Hyaluronic acid, Social media, Government, Vitamin, Microinjection, Restylane, Collagen, Mesoderm, Filler (linguistics), Female, Day spa, Pharmaceutical industry

Also, this simply helps aid in the hydration process, which is fundamental for a youthful glow.

Key Points: 
  • Also, this simply helps aid in the hydration process, which is fundamental for a youthful glow.
  • Unlike dermal fillers, skin boosters are not for wrinkle reduction or augmentation, their role is to primarily hydrate the skin and promote the formation of new collagen and elastin to give the skin a firmer appearance.
  • However, since the government in many countries has allowed resuming elective aesthetic procedures the demand has been on the rise.
  • The female segment held the highest market in 2022 share women are more willing to undergo cosmetic treatment.

Therapeutic Solutions International Announces Antigen Specific Blockade of Pathological Immune Response in Multiple Sclerosis Model Using “Tattoo Gun” Immunization

Retrieved on: 
Wednesday, January 4, 2023
Pharmaceutical, Health, Medical Devices, Peptide, Holy Grail, TSOI, Consultant, Inflammation, Disease, Pregnancy, Tissue, Sclerosis, AIRE, Myelin basic protein, Microinjection, Immunity, Transfection, Patent, FOXP3, Vaccine

Previously other groups have used tattoo gun-based mechanisms to stimulate immune responses based on the theoretical advantage that a high number of microinjections results in a greater number of antigen presenting cells received to target immunogens.

Key Points: 
  • Previously other groups have used tattoo gun-based mechanisms to stimulate immune responses based on the theoretical advantage that a high number of microinjections results in a greater number of antigen presenting cells received to target immunogens.
  • “Utilizing a “tattoo gun” approach evokes a substantial degree of inflammation, which is classically believed to stimulate immunity.
  • “It would be extremely ironic if something as simple as a tattoo gun was the answer.”
    The concept of modulating antigen presentation to inhibit pathological immunity has previously been described.
  • However, the unexpected potency of the large surface area of injection only achievable by a tattoo gun was completely unexpected.

Global Mice Model Market (2022 to 2027) - Rise of CRISPR as a Powerful Tool in the Field of Biomedical Research Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Other Science, Science, Transfer, Quarantine, Investment, Observation, Geography, Impact, SWOT, Ansoff Matrix, USD, CRISPR, Feed, Genetic testing, Emotion, Market development, COVID-19, Competitive analysis, Growth, Porter's five forces analysis, Microinjection, Others, Risk, Pharmaceutical industry, Marketing, Risk management, Retail, Medical device, Service, Breeding, Cryopreservation

The report presents a detailed Ansoff matrix analysis for the Global Mice Model Market.

Key Points: 
  • The report presents a detailed Ansoff matrix analysis for the Global Mice Model Market.
  • The analyst analyses the Global Mice Model Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The Global Mice Model Market is segmented based on Type, Services, Technology, Mice Care Products, Applications, and Geography.
  • By Type, the market is classified into Conditioned/Surgically Modified Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, Inbred Mice, Outbred Mice, and Spontaneous Mutant Mice.

Global Rat Model Market Research 2022-2027: Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area - ResearchAndMarkets.com

Retrieved on: 
Friday, July 22, 2022
Health, Other Health, Transfer, SWOT, Investment, Others, COVID-19, Market development, Environmental impact of pharmaceuticals and personal care products, Microinjection, Industry, Genetic testing, Risk, Quarantine, Inflammation, USD, Ansoff Matrix, Geography, CAGR, Clinical trial, Horizon Discovery, Taconic Biosciences, Children's Environmental Exposure Research Study, Neurology, Rat, Emotion, Competitive analysis, Diabetes, Impact, Growth, Pharmaceutical industry, Retail, Risk management, Trapping, Cryopreservation, Cages, Envigo, Technology, CRISPR, Toxicology, Breeding

The "Global Rat Model Market (2022-2027) by Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Rat Model Market (2022-2027) by Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Market dynamics are forces that impact the prices and behaviors of the Global Rat Model Market stakeholders.
  • The report analyses the Global Rat Model Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • By Clinical Trials & Research, the market is classified into Clinical Trials, and Research Studies.

Global RNA Based Therapeutic Market to 2027 - Rising Popularity of Personalized Medicines is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 20, 2022
Health, Pharmaceutical, Diabetes, Death, Breast, RNA transfection, Conditional sentence, Tuberculosis, Patient, Infection, Prostate, AIDS, Disorder, RNA interference, Lipid, Stomach, Half-life, Microinjection, Nanoparticle, Salt, Thyroid cancer, WHO, Liver cancer, Global, RNA, Sequencing, Therapy, Lung, Immune system, CAGR, Acid, Application, Drug discovery, Growth, Pharmaceutical industry, Vaccine, Cancer

The Global RNA Based Therapeutic Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 15.1 % CAGR during the forecast period.

Key Points: 
  • The Global RNA Based Therapeutic Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 15.1 % CAGR during the forecast period.
  • RNAi and antisense technology are gaining popularity in the research business because they give the base sequence for developing RNA therapeutics.
  • The desire for cures for infectious diseases and cancer is projected to influence the growth of the global RNA-based therapies and vaccine market.
  • Due to RNA-based therapeutic, the practitioners are allowed to provide patients with personalized medicines based on their bodies' needs.

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 11, 2022
Research, U.S. Securities and Exchange Commission, Webcast, Macular edema, Cohort, Conference, CLS, Private Securities Litigation Reform Act, SEC, Annual report, ET, Drug development, Annual general meeting, Toxic leukoencephalopathy, SCS, Axitinib, Clinical trial, Investor, COVID-19, Periodic Report of the United States of America to the United Nations Committee Against Torture, ARVO, GLOBE, Uveitis, Company, Foundation, Pharming, Eye, Association, Conference call, Refractive surgery, Bausch & Lomb, Choroid, Retina, Patient, NASDAQ, Association for Research in Vision and Ophthalmology, Society, AMD, ASCRS, Safety, Sale, Cataract, Microinjection, Pharmaceutical industry, Video game, Risk management, Ophthalmology, Clearside

ALPHARETTA, Ga., May 11, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., May 11, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • Clearsides license and other revenue for the first quarter of 2022 was $347,000, compared to $34,000 for the first quarter of 2021.
  • Research and development expenses for the first quarter of 2022 were $4.5 million, compared to $5.5 million for the first quarter of 2021.
  • Clearsides management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

The Worldwide Intradermal Injection Industry is Expected to Reach $7.4 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 23, 2022
Health, Medical Devices, Other Health, Population, Death, Growth, WHO, COVID-19, Method, World, Smallpox vaccine, Tuberculosis, Microinjection, TB, World Health Organization, Student, CAGR, Incidence, Pharmaceutical industry, Vaccine, Application

The "Intradermal injection Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Method, Application, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intradermal injection Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Method, Application, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The intradermal injection market is projected to reach US$ 7,415.70 million by 2028 from US$ 3,513.26 million in 2021 and is expected to register a CAGR of 11.3% from 2021 to 2028.
  • The World Health Organization (WHO) recognizes waste reduction in healthcare delivery as an important aspect of strengthening health systems.
  • Therefore, the efficacy of intradermal infection is increasing continuously, indicating the bright future of this segment.